DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Cardiobase

New data demonstrating that Cosentyx ( Secukinumab ) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable sa ...


The results of a phase I study in advanced melanoma suggested complementary clinical activity with Nivolumab ( Opdivo ), a PD-1 checkpoint inhibitor, plus Ipilimumab ( Yervoy ), a CTLA-4 checkpoint in ...


Keytruda ( Pembrolizumab ) is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with ...


Rosmarinus officinalis L. is a medicinal plant with diverse activities including enhancement microcapillary perfusion. A study has investigated the clinical efficacy of rosemary oil in the treatment ...


Rosmarinus officinalis L. is a medicinal plant with diverse activities including enhancement microcapillary perfusion. A study aimed to investigate the clinical efficacy of rosemary oil in the tre ...


Phase II trial results from investigational compound BI 655066 were presented at 73rd Annual Meeting of the American Academy of Dermatology. Nearly double the percentage of patients with moderate-to ...


In clinical practice, patients with psoriasis may require intermittent therapy as part of their long-term treatment programme. Those achieving Physician's Global Assessment ( PGA ) of less than or equ ...


Finasteride ( Propecia ) at a dose of 1 mg/d has been reported to show no significant improvement in 30–50% of patients with androgenetic alopecia. Dutasteride ( Avodart ), a dual inhibitor of both ...


The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7-20%. The use of tumor necrosis factor-alpha ( TNF-alpha ) inhibitors as a treatment for refractory uveitis is ...


The phase IIIb CLEAR study for Secukinumab ( Cosentyx ) has demonstrated superiority to Ustekinumab ( Stelara ) and met its primary endpoint of achieving PASI 90, which represents clear or almost clea ...


Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-alpha therapy on the mechanisms associate ...


Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program were presented at the 23rd European Academy of Dermatology and Venereolog ...


The Dermatologic and Ophthalmic Drugs Advisory Committee ( DODAC ) to the US Food and Drug Administration ( FDA ) has voted unanimously to support the approval of AIN457 ( Secukinumab ), a selective i ...


Results from a phase 2b dose-ranging study of Dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema were presented. All ...


Results from a phase 3 pivotal study demonstrating that Adalimumab ( Humira ) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa ( HS ), specifi ...